Patient-Focused Treatment Decisions in Metastatic Melanoma: An In-Depth Look at the Role of Checkpoint Inhibitors

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bristol Myers Squibb and Merck & Dohme Corp.

Melanoma is the most serious and deadly type of skin cancer and according to the National Cancer Institute, will affect about 73,870 people in 2019. Although melanoma is predominately found in the skin, it occurs in melanocytes and may metastasize to any area of the body that contains melanocytes. In the early stages of melanoma, prognosis is usually good for patients but when the melanoma becomes metastatic and spreads to other areas of the body, prognosis is especially poor. For people with stage IV disease, the melanoma has spread beyond the local area into other areas or organs. The most common sites of such spread (metastases) are under the skin (subcutaneous tissue) and other soft tissues (including lymph nodes), the lungs, liver, brain, and bone. In stage IV metastatic melanoma, the goal of treatment is to shrink or get rid of the metastases and prevent the disease from spreading. Recently several new immunotherapies have become available for patients with advanced melanoma, especially in varying treatment settings. These therapies help the immune system sustain an active response in its attack on melanoma cells.

Upon completion of this activity, participants will be able to:

  • Analyze recent efficacy and safety data regarding the use of immune checkpoint inhibitors as adjuvant treatment for patients with advanced melanoma

  • Explore recent clinical data on checkpoint inhibitors in the first-line treatment in metastatic melanoma

  • Identify patients with advanced melanoma who may benefit from combination immune checkpoint inhibitor-based treatment

  • Assess the latest evidence regarding the use of checkpoint inhibitors in patients with melanoma brain metastases and the resulting clinical implications

  • Examine immune-related adverse events (irAEs) that may occur with the use of immune checkpoint inhibitors and how they should be identified and managed for improved patient adherence and quality of life

  • Explore managed care considerations surrounding recent updates in the use of immune checkpoint inhibitors as adjuvant treatment and in combinations for patients with advanced melanoma

Faculty: Ragini Kudchadkar, MD
Associate Professor
Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University


Dr. Kudchadkar serves on an advisory board for Array, BMS, Novartis, and Regeneron. She has received grant/research support from BMS, Merck, and Regeneron. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bristol Myers Squibb and Merck & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue